ELISA/assay

Human Dopamine Receptor D2 ELISA Kit

MBS723432

48-Strip-Wells

470 USD

ELISA Kit

Human Dopamine Receptor D2 ELISA Kit

Dopamine Receptor D2

dopamine receptor D2; D(2) dopamine receptor; D(2) dopamine receptor; D(2) dopamine receptor; dopamine D2 receptor; dopamine receptor D2 isoform; seven transmembrane helix receptor; dopamine receptor D2; Dopamine D2 receptor

DRD2

DRD2; DRD2; D2R; D2DR

DRD2_HUMAN

Human

Store all reagents at 2-8 degree C.

Samples: Serum, plasma, Cell Culture Supernatants, body fluid and tissue homogenate. Assay Type: Competitive. Sensitivity: 0.1 ng/mL.

Intended Uses: This DRD2 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human DRD2. This ELISA kit for research use only, not for therapeutic or diagnostic applications!

Neurobiology

For samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate . INTENDED USE This DRD2 ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human DRD2. This ELISA kit for researchuse only, not for therapeutic or diagnostic applications! . PRINCIPLE OF THE ASSAY DRD2 ELISA kit applies the competitive enzyme immunoassay technique utilizing a monoclonal anti-DRD2 antibody and an DRD2-HRP conjugate. The assay sample and buffer are incubated together with DRD2-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the DRD2 concentration since DRD2 from samples and DRD2-HRP conjugate compete for the anti-DRD2 antibody binding site. Since the number of sites is limited, as more sites are occupied by DRD2 from the sample, fewer sites are left to bind DRD2-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The DRD2 concentration in each sample is interpolated from this standard curve.

5921480

CAB56463.1

P14416

50,847 Da

Alcoholism Pathway (585563); Alcoholism Pathway (587116); Amine Ligand-binding Receptors Pathway (106363); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Cocaine Addiction Pathway (546258); Cocaine Addiction Pathway (546273); Dopamine Receptors Pathway (106366); Dopaminergic Synapse Pathway (469199); Dopaminergic Synapse Pathway (469185); G Alpha (i) Signalling Events Pathway (119550)

This gene encodes the D2 subtype of the dopamine receptor. This G-protein coupled receptor inhibits adenylyl cyclase activity. A missense mutation in this gene causes myoclonus dystonia; other mutations have been associated with schizophrenia. Alternative splicing of this gene results in two transcript variants encoding different isoforms. A third variant has been described, but it has not been determined whether this form is normal or due to aberrant splicing. [provided by RefSeq, Jul 2008]

DRD2: Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Defects in DRD2 are associated with dystonia type 11 (DYT11); also known as alcohol-responsive dystonia. DYT11 is a myoclonic dystonia. Dystonia is defined by the presence of sustained involuntary muscle contractions, often leading to abnormal postures. DYT11 is characterized by involuntary lightning jerks and dystonic movements and postures alleviated by alcohol. Inheritance is autosomal dominant. The age of onset, pattern of body involvement, presence of myoclonus and response to alcohol are all variable. Belongs to the G-protein coupled receptor 1 family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Membrane protein, integral; Membrane protein, multi-pass; GPCR, family 1; Receptor, GPCR. Chromosomal Location of Human Ortholog: 11q23. Cellular Component: synaptic vesicle membrane; endocytic vesicle; axon; integral to plasma membrane; postsynaptic density; dendrite; plasma membrane; dendritic spine; acrosome; perikaryon; nerve terminal; lateral plasma membrane. Molecular Function: dopamine D2 receptor-like receptor activity; identical protein binding; ionotropic glutamate receptor binding; protein binding; protein homodimerization activity; potassium channel regulator activity; protein heterodimerization activity; dopamine binding; drug binding. Biological Process: response to nicotine; elevation of cytosolic calcium ion concentration during G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); prepulse inhibition; positive regulation of dopamine uptake; response to toxin; positive regulation of receptor internalization; positive regulation of multicellular organism growth; regulation of phosphoprotein phosphatase activity; thermoregulation; adult walking behavior; dopamine metabolic process; dopamine receptor, adenylate cyclase inhibiting pathway; negative regulation of insulin secretion; protein localization; phosphatidylinositol metabolic process; negative regulation of blood pressure; response to drug; response to inactivity; positive regulation of neuroblast proliferation; response to light stimulus; cerebral cortex GABAergic interneuron migration; negative regulation of synaptic transmission, glutamatergic; regulation of sodium ion transport; arachidonic acid secretion; regulation of synaptic transmission, GABAergic; positive regulation of growth hormone secretion; G-protein coupled receptor internalization; reduction of cytosolic calcium ion concentration; activation of protein kinase activity; positive regulation of transcription from RNA polymerase II promoter; regulation of long-term neuronal synaptic plasticity; synaptic transmission, dopaminergic; peristalsis; branching morphogenesis of a nerve; negative regulation of circadian sleep/wake cycle, sleep; response to morphine; locomotory behavior; behavioral response to ethanol; orbitofrontal cortex development; negative regulation of cell proliferation; synaptogenesis; behavioral response to cocaine; adenohypophysis development; visual learning; nerve-nerve synaptic transmission; feeding behavior; circadian regulation of gene expression; response to axon injury; negative regulation of dopamine secretion; negative regulation of cell migration; response to iron ion; associative learning; positive regulation of cytokinesis; grooming behavior; negative regulation of protein secretion; negative regulation of protein kinase B signaling cascade; Wnt receptor signaling pathway; striatum development; regulation of cAMP metabolic process; regulation of heart rate; regulation of potassium ion transport; sensory perception of smell; negative regulation of adenylate cyclase activity; response to amphetamine; regulation of dopamine uptake; auditory behavior; response to cocaine; cellular calcium ion homeostasis; regulation of systemic arterial blood pressure by neurological process; negative regulation of dopamine receptor signaling pathway; long-term memory; pigmentation; axonogenesis; release of sequestered calcium ion into cytosol; positive regulation of G-protein coupled receptor protein signaling pathway; response to hypoxia; regulation of synapse structural plasticity; dopamine receptor, phospholipase C activating pathway. Disease: Myoclonic Dystonia

48-Strip-Wells

470 USD

96-Strip-Wells

675